Abstract
Although
among
the
six
most
common
parasitic
diseases,
leishmaniasis
is
considered
a
neglected
disease,
being
recognised
as
serious
public
health
burden
worldwide.
This
fact
impairs
technological
advancements
and
investments
in
innovative
therapeutic
approaches,
so
that
commonly
available
drugs
are
still
associated
with
low
rates
significant
side
effects.
Pentavalent
antimonials,
such
Pentostan
®
Glucantime
,
were
established
chemotherapeutic
agents
since
1940s,
first
line
of
treatment
for
leishmaniasis;
however,
60%
cases
resistant
to
pentavalent
antimonials.
Thus,
search
more
effective
therapies
new
potential
leishmanicidal
activity
in-demand.
In
this
review,
an
overview
about
disease
its
pathophysiology
given,
discussing
current
state-of-the-art
standard
treatments
alternatives
based
on
drug
delivery
enhancing
need
pharmaceutical
treatments.
Molecules,
Год журнала:
2020,
Номер
25(11), С. 2602 - 2602
Опубликована: Июнь 3, 2020
Neglected
tropical
diseases
such
as
Chagas
disease
and
leishmaniasis
affect
millions
of
people
around
the
world.
Both
various
parts
globe
drugs
traditionally
used
in
therapy
against
these
have
limitations,
especially
with
regard
to
low
efficacy
high
toxicity.
In
this
context,
class
bisphosphonate-based
compounds
has
made
significant
advances
regarding
chemical
synthesis
process
well
pharmacological
properties
attributed
compounds.
Among
spectrum
activity,
bisphosphonate
antiparasitic
activity
stand
out,
treatment
caused
by
Trypanosoma
cruzi
Leishmania
spp.,
respectively.
Some
can
inhibit
mevalonate
pathway,
an
essential
metabolic
interfering
ergosterol,
a
sterol
responsible
for
growth
viability
parasites.
Therefore,
review
aims
present
information
about
importance
agents
potential
new
treat
leishmaniasis.
Antimicrobial Agents and Chemotherapy,
Год журнала:
2022,
Номер
66(11)
Опубликована: Окт. 31, 2022
Drug
combinations
and
drug
repurposing
have
emerged
as
promising
strategies
to
develop
novel
treatments
for
infectious
diseases,
including
Chagas
disease.
In
this
study,
we
aimed
investigate
whether
the
repurposed
drugs
chloroquine
(CQ)
colchicine
(COL),
known
inhibit
Trypanosoma
cruzi
infection
in
host
cells,
could
boost
anti-
T.
effect
of
trypanocidal
benznidazole
(BZN),
increasing
its
therapeutic
efficacy
while
reducing
dose
needed
eradicate
parasite.
The
combination
BZN
COL
exhibited
cytotoxicity
infected
cells
low
antiparasitic
activity.
Research and Reports in Tropical Medicine,
Год журнала:
2023,
Номер
Volume 14, С. 61 - 85
Опубликована: Июль 1, 2023
Leishmaniasis
is
a
neglected
tropical
disease
endemic
primarily
to
low-and
middle-income
countries,
for
which
there
has
been
inadequate
development
of
affordable,
safe,
and
efficacious
therapies.Clinical
manifestations
leishmaniasis
range
from
selfhealing
skin
lesions
lethal
visceral
infection
with
chances
relapse.Although
treatments
are
available,
secondary
effects
limit
their
use
outside
the
clinic
negatively
impact
quality
life
patients
in
areas.Other
non-medicinal
treatments,
such
as
thermotherapies,
limited
cutaneous
but
not
infection.Recent
studies
shed
light
mechanisms
through
Leishmania
can
persist
by
hiding
cellular
safe
havens,
even
after
chemotherapies.This
review
focuses
on
exploring
niches
that
parasites
may
be
leveraging
within
host.Also,
cellular,
metabolic,
molecular
implications
how
those
could
targeted
therapeutic
purposes
discussed.Other
therapies,
developed
against
cancer
or
manipulation
ferroptosis
pathway,
proposed
possible
due
action.In
particular,
target
hematopoietic
stem
cells
monocytes,
have
recently
found
necessary
components
sustain
provide
niche
discussed
this
potential
field-deployable
leishmaniasis.
Abstract
Although
among
the
six
most
common
parasitic
diseases,
leishmaniasis
is
considered
a
neglected
disease,
being
recognised
as
serious
public
health
burden
worldwide.
This
fact
impairs
technological
advancements
and
investments
in
innovative
therapeutic
approaches,
so
that
commonly
available
drugs
are
still
associated
with
low
rates
significant
side
effects.
Pentavalent
antimonials,
such
Pentostan
®
Glucantime
,
were
established
chemotherapeutic
agents
since
1940s,
first
line
of
treatment
for
leishmaniasis;
however,
60%
cases
resistant
to
pentavalent
antimonials.
Thus,
search
more
effective
therapies
new
potential
leishmanicidal
activity
in-demand.
In
this
review,
an
overview
about
disease
its
pathophysiology
given,
discussing
current
state-of-the-art
standard
treatments
alternatives
based
on
drug
delivery
enhancing
need
pharmaceutical
treatments.
